Education · Tier 5

· Last Reviewed May 15, 2026· PSI Editorial Board· Independent

How Does the US Pharmacy Compounding System Work?

The regulatory framework reference for US pharmacy compounding anchored in FDA Compounding Quality Act of 2013, USP General Chapters 797 and 800, PCAB accreditation, and AMA Code of Medical Ethics 1.1.5.

US pharmacy compounding operates under the FDA Compounding Quality Act of 2013.

The framework establishes two compounding categories.

The 503A pathway covers state-licensed traditional compounding pharmacies.

The 503B pathway covers FDA-registered outsourcing facilities.

2013

Compounding Quality Act

FDA Compounding Quality Act of 2013 (Drug Quality and Security Act) establishes 503A and 503B framework

503A

Traditional Pharmacy Pathway

State pharmacy board licensed compounding pharmacies with patient-specific prescription requirements

503B

Outsourcing Facility Pathway

FDA-registered outsourcing facilities authorized for office-administered compounded preparations

USP 797

Sterile Standards

USP General Chapter 797 sterile compounding standards plus USP General Chapter 800 hazardous drug handling

Quick Answer

US pharmacy compounding operates under the FDA Compounding Quality Act of 2013. The framework operates under the Drug Quality and Security Act. Neither compounding category receives FDA pre-market approval for the compounded product.

The 503A pathway covers traditional compounding pharmacies. The pathway operates under state pharmacy board licensure. The pharmacy must be licensed by the state pharmacy board where it operates. Each compounded preparation requires a patient-specific prescription from a state medical board licensed physician. Verification is through the state pharmacy board portal for the operating state. See Compounded vs FDA-Approved Peptides for the prescribing framework.

The 503B pathway covers outsourcing facilities. The pathway operates under FDA registration as authorized by the FDA Compounding Quality Act. The 503B facility may produce compounded preparations without patient-specific prescriptions for office-administered use. Verification is through the FDA Drug Establishment Registration database. The 503B framework supports larger-volume compounded preparation for healthcare provider offices.

Quality assurance includes Pharmacy Compounding Accreditation Board (PCAB) accreditation. PCAB accreditation provides additional quality verification through the PCAB website. USP General Chapter 797 sterile compounding standards address aseptic technique, environmental monitoring, beyond-use dating, and personnel qualification. USP General Chapter 800 hazardous drug handling standards address worker and patient safety.

The FDA shortage list framework permits temporary compounding of FDA-approved drugs during documented shortages. Compounded semaglutide and compounded tirzepatide during FDA shortage list inclusion windows operated under this framework. Salt-form variants of FDA-approved molecules face FDA enforcement and do not qualify under shortage list compounding.

AMA Code of Medical Ethics 1.1.5 framework governs off-label and compounded prescribing. The framework requires documented risk-benefit assessment, FDA-approved alternatives considered, monitoring requirements, and patient understanding. See Peptides 101 for the broader context. See Evidence Levels Explained for the PSI framework.

Neither category receives FDA pre-market approval for the compounded product. The 503A pathway covers state-licensed pharmacies. The 503B pathway covers FDA-registered outsourcing facilities. PCAB accreditation provides additional quality verification. USP Chapter 797 addresses sterile compounding. USP Chapter 800 addresses hazardous drug handling. The FDA shortage list permits temporary compounding during documented shortages. AMA Code 1.1.5 governs compounded prescribing.

COMPOUNDING SYSTEM REFERENCE

At a Glance: The Compounding Pharmacy System

Framework Element	Subtitle	Animal Evidence	Human Evidence	Regulatory Anchoring
FDA Compounding Quality Act of 2013	Drug Quality and Security Act framework	—	Strong	Establishes 503A traditional compounding pharmacy and 503B outsourcing facility framework with quality assurance requirements
503A traditional compounding pharmacy	State pharmacy board licensed pathway	—	Strong	Patient-specific prescription required. State license verification through state pharmacy board portal for operating state
503B outsourcing facility	FDA-registered pathway for office-administered preparations	—	Strong	May produce compounded preparations without patient-specific prescriptions for healthcare provider offices. FDA Drug Establishment Registration verification
PCAB accreditation	Pharmacy Compounding Accreditation Board verification	—	Moderate	Additional quality verification beyond state pharmacy board licensure or FDA registration. PCAB website verification
USP General Chapter 797	Sterile compounding standards	—	Strong	Aseptic technique, environmental monitoring, beyond-use dating, personnel qualification for sterile preparations including injectable peptides
USP General Chapter 800	Hazardous drug handling standards	—	Strong	Worker and patient safety protocols for hazardous drug compounding including some peptide and biologic preparations
FDA shortage list compounding framework	Temporary compounding during documented shortages	—	Moderate	Permits compounded semaglutide and compounded tirzepatide during FDA shortage list inclusion windows. Salt-form variants face FDA enforcement
AMA Code of Medical Ethics 1.1.5	Off-label and compounded prescribing framework	—	Strong	Risk-benefit assessment, FDA-approved alternatives considered, monitoring requirements, patient understanding through informed consent

Six Things You Need to Know About Pharmacy Compounding

This page covers the US pharmacy compounding system regulatory framework. Section one covers the FDA Compounding Quality Act of 2013 and the 503A versus 503B framework distinction. Section two covers PCAB accreditation and quality assurance. Section three covers USP General Chapters 797 and 800 standards. Section four covers the FDA shortage list compounding framework and the AMA Code 1.1.5 prescribing framework.

The FDA Compounding Quality Act of 2013 Establishes the Framework

The FDA Compounding Quality Act of 2013 operates under the Drug Quality and Security Act framework. The framework establishes two compounding categories: 503A traditional compounding pharmacies and 503B outsourcing facilities. Neither category receives FDA pre-market approval for the compounded product.

The FDA Compounding Quality Act of 2013 was enacted in response to the 2012 New England Compounding Center meningitis outbreak which caused over 60 deaths. The Drug Quality and Security Act established two distinct compounding pathways with different regulatory oversight. The 503A pathway covers traditional compounding under state pharmacy board licensure. The 503B pathway covers outsourcing facilities under FDA registration. The framework operates under section 503 of the Federal Food, Drug, and Cosmetic Act. The framework allows compounded preparations for legitimate medical need while addressing the patient safety concerns raised by the 2012 outbreak. Neither pathway receives FDA pre-market approval for the compounded product. The compounded product is prepared in accordance with patient-specific prescription (503A) or office-administered authorization (503B) rather than reviewed for safety and efficacy by FDA. AMA Code of Medical Ethics 1.1.5 framework governs the prescribing decision for both pathways. Quality assurance includes Pharmacy Compounding Accreditation Board accreditation and compliance with USP General Chapters 797 (sterile compounding) and 800 (hazardous drug handling).

503A Traditional Compounding Pharmacies Operate Under State Pharmacy Board Licensure

503A traditional compounding pharmacies operate under state pharmacy board licensure. Each compounded preparation requires a patient-specific prescription from a state medical board licensed physician. The pathway covers traditional pharmacist-prepared compounded medications.

The 503A pathway covers traditional compounding pharmacy operations under state pharmacy board licensure. The pharmacy must hold a current state pharmacy board license in the state where it operates. License verification is through the state pharmacy board portal for the operating state. Each compounded preparation requires a patient-specific prescription from a state medical board licensed physician. The patient-specific requirement distinguishes 503A from 503B. The 503A pathway supports traditional compounding contexts including compounded peptide preparations (thymosin alpha-1, BPC-157, sermorelin, compounded GLP-1 during shortage list windows), compounded hormone therapy, compounded medications for patients with documented allergies to commercial product excipients, compounded medications in specific dose forms not commercially available, and many other legitimate compounding contexts. The pharmacy operates under state pharmacy board oversight including periodic inspection, complaint review, and compliance monitoring. Quality assurance requirements include USP Chapter 797 sterile compounding compliance for sterile preparations and USP Chapter 800 hazardous drug handling compliance where applicable. PCAB accreditation provides additional voluntary quality verification.

503B Outsourcing Facilities Operate Under FDA Registration

503B outsourcing facilities operate under FDA registration as authorized by the FDA Compounding Quality Act. The pathway may produce compounded preparations without patient-specific prescriptions for office-administered use by healthcare providers.

The 503B pathway covers FDA-registered outsourcing facilities. The facility must register with FDA as an outsourcing facility under section 503B. FDA registration verification is through the FDA Drug Establishment Registration database. The 503B framework permits production of compounded preparations without patient-specific prescriptions for office-administered use by healthcare providers. The pathway supports clinic-administered compounded preparations including some peptide preparations for office injection contexts. The 503B facility operates under FDA inspection authority with periodic FDA inspections. The framework requires compliance with current good manufacturing practice (cGMP) standards adapted for compounding. Quality assurance requirements include USP Chapter 797 sterile compounding compliance, USP Chapter 800 hazardous drug handling compliance, environmental monitoring, beyond-use dating validation, and third-party testing for purity and potency. The 503B framework operates with higher volume capacity than typical 503A pharmacies. The framework supports office-administered compounded preparation in larger quantities for healthcare provider offices.

PCAB Accreditation Provides Additional Quality Verification

Pharmacy Compounding Accreditation Board (PCAB) accreditation provides additional voluntary quality verification beyond state pharmacy board licensure or FDA registration. PCAB accreditation applies to both 503A and 503B facilities.

PCAB accreditation is provided by the Pharmacy Compounding Accreditation Board, an independent accreditation body. PCAB accreditation is voluntary but provides additional quality verification beyond mandatory state pharmacy board licensure (for 503A) or FDA registration (for 503B). PCAB accreditation requires compliance with PCAB standards covering pharmacy operations, sterile compounding (where applicable), non-sterile compounding (where applicable), and quality management. Accreditation includes on-site inspection by PCAB inspectors. PCAB accredited pharmacies and outsourcing facilities are listed on the PCAB website. The accreditation supports quality assurance verification for healthcare providers selecting compounding pharmacy partners. The accreditation supports patient confidence in compounded preparation quality. Verification is through the PCAB website search functionality. Healthcare providers ordering compounded preparations frequently verify PCAB accreditation status as one of multiple quality verification steps. The accreditation is typically renewed on multi-year cycles with re-inspection requirements.

USP General Chapters 797 and 800 Establish Compounding Quality Standards

USP General Chapter 797 establishes sterile compounding standards. USP General Chapter 800 establishes hazardous drug handling standards. Both standards apply across 503A and 503B operations as relevant.

USP General Chapter 797 establishes sterile compounding standards for pharmaceutical compounding. The chapter covers aseptic technique requirements, environmental monitoring including air sampling and surface sampling, beyond-use dating for sterile preparations, personnel qualification and training requirements, garbing and hand hygiene protocols, and quality assurance documentation. The chapter applies to all sterile preparations including injectable peptide preparations. Compliance is required for both 503A pharmacies (where preparing sterile compounded medications) and 503B outsourcing facilities. USP General Chapter 800 establishes hazardous drug handling standards. The chapter covers worker safety protocols for hazardous drug compounding, patient safety protocols, environmental controls including containment primary engineering controls, personal protective equipment requirements, spill management procedures, and waste handling protocols. The chapter applies to facilities preparing hazardous drugs as defined by NIOSH (National Institute for Occupational Safety and Health). Some peptide and biologic preparations may be classified as hazardous drugs requiring USP 800 compliance. Compliance with USP 797 and 800 standards is monitored through state pharmacy board inspection (for 503A) and FDA inspection (for 503B). PCAB accreditation also verifies USP 797 and 800 compliance.

FDA Shortage List Compounding Framework Has Specific Requirements

The FDA shortage list compounding framework permits temporary compounding of FDA-approved drugs during documented shortages. The framework applied to compounded semaglutide and compounded tirzepatide during shortage list inclusion windows. Salt-form variants face FDA enforcement.

The FDA shortage list framework operates under section 503A and 503B of the Federal Food, Drug, and Cosmetic Act with FDA enforcement discretion. The framework permits compounded preparation of drugs that are essentially copies of FDA-approved drugs only when the FDA-approved drug is on the FDA shortage list. The shortage list is published and updated by FDA at the FDA Drug Shortage Database. Compounding under shortage list framework operates while the drug is on the shortage list. When FDA removes the drug from the shortage list, the framework no longer permits compounding. Examples include compounded semaglutide preparation that operated under the framework while semaglutide was on the FDA shortage list. FDA removed semaglutide from the shortage list in October 2024 ending the framework window. Compounded tirzepatide operated similarly while tirzepatide was on the shortage list. FDA removed tirzepatide from the shortage list in December 2024. Salt-form variants of FDA-approved molecules face FDA enforcement and do not qualify under shortage list compounding. Examples include semaglutide sodium and semaglutide acetate which are not the FDA-approved semaglutide base molecule. The FDA has issued warning letters and enforcement actions against compounding of salt-form variants outside the shortage list framework.

503A vs 503B: traditional pharmacy vs outsourcing facility

Two distinct compounding pathways under the FDA Compounding Quality Act of 2013

The 503A pathway covers traditional compounding pharmacies under state pharmacy board licensure. Each compounded preparation requires a patient-specific prescription from a state medical board licensed physician. The patient-specific requirement is the defining characteristic. State license verification is through the state pharmacy board portal for the operating state. The pathway supports traditional pharmacist-prepared compounded medications across many indications including compounded peptide preparations.

Both pathways operate under the FDA Compounding Quality Act of 2013 (Drug Quality and Security Act framework). Neither receives FDA pre-market approval for the compounded product. The 503A pathway operates under state pharmacy board oversight including periodic inspection. The 503B pathway operates under FDA inspection authority with periodic FDA inspections. Quality assurance requirements include USP Chapter 797 sterile compounding compliance and USP Chapter 800 hazardous drug handling compliance for both pathways. PCAB accreditation provides additional voluntary quality verification.

Quality assurance framework: PCAB, USP 797, USP 800, third-party testing

Multi-layered quality verification for compounded peptide preparations

Pharmacy Compounding Accreditation Board (PCAB) accreditation provides additional voluntary quality verification beyond mandatory state pharmacy board licensure or FDA registration. PCAB accreditation requires compliance with PCAB standards covering pharmacy operations, sterile compounding, non-sterile compounding, and quality management. Accreditation includes on-site inspection by PCAB inspectors. Verification is through the PCAB website search functionality.

USP General Chapter 797 establishes sterile compounding standards. The chapter covers aseptic technique, environmental monitoring including air and surface sampling, beyond-use dating for sterile preparations, personnel qualification and training, garbing and hand hygiene protocols, and quality assurance documentation. The chapter applies to all sterile preparations including injectable peptide preparations. USP General Chapter 800 establishes hazardous drug handling standards. The chapter covers worker safety protocols, patient safety protocols, environmental controls, personal protective equipment, spill management, and waste handling.

Third-party testing supplements the regulatory framework. Testing typically includes USP General Chapter 71 sterility testing, USP General Chapter 85 bacterial endotoxin testing, and HPLC potency analysis for active ingredient verification. Some compounding pharmacies provide certificate of analysis documentation per compounded preparation batch. Healthcare providers ordering compounded preparations frequently verify quality assurance documentation as part of pharmacy partner selection.

FDA shortage list compounding framework: semaglutide and tirzepatide history

Temporary compounding authorization during documented FDA shortage list inclusion

The FDA shortage list compounding framework operates under section 503A and 503B of the Federal Food, Drug, and Cosmetic Act with FDA enforcement discretion. The framework permits compounded preparation of drugs that are essentially copies of FDA-approved drugs only when the FDA-approved drug is on the FDA shortage list. The shortage list is published and updated by FDA at the FDA Drug Shortage Database.

Compounded semaglutide operated under this framework while semaglutide was on the FDA shortage list. FDA placed semaglutide on the shortage list in March 2022 due to manufacturing capacity constraints with Novo Nordisk. The framework permitted compounded semaglutide preparation through 503A and 503B pathways. FDA removed semaglutide from the shortage list in October 2024 ending the framework window. Compounded tirzepatide operated similarly. FDA placed tirzepatide on the shortage list in 2022 due to manufacturing capacity constraints with Eli Lilly. FDA removed tirzepatide from the shortage list in December 2024.

Salt-form variants of FDA-approved molecules face FDA enforcement and do not qualify under the shortage list framework. Semaglutide sodium and semaglutide acetate are not the FDA-approved semaglutide base molecule. The FDA has issued warning letters and enforcement actions against compounding of salt-form variants outside the shortage list framework. Healthcare providers ordering compounded GLP-1 receptor agonist preparations after the shortage list windows ended must consider the current regulatory framework including FDA enforcement priorities and AMA Code of Medical Ethics 1.1.5 documentation requirements.

Research Suggests

Direction

US pharmacy compounding operates under the FDA Compounding Quality Act of 2013 establishing 503A and 503B pathways. Quality assurance includes PCAB accreditation, USP standards, and AMA Code 1.1.5 framework.

The FDA Compounding Quality Act of 2013 (Drug Quality and Security Act framework) establishes two compounding categories. The 503A pathway covers traditional compounding pharmacies under state pharmacy board licensure with patient-specific prescription requirements. The 503B pathway covers FDA-registered outsourcing facilities authorized for office-administered preparations. Quality assurance includes Pharmacy Compounding Accreditation Board accreditation (voluntary additional verification), USP General Chapter 797 sterile compounding standards, USP General Chapter 800 hazardous drug handling standards, and third-party testing. The FDA shortage list framework permits temporary compounding of FDA-approved drugs during documented shortages. Compounded semaglutide and tirzepatide operated under this framework during shortage list inclusion windows. AMA Code of Medical Ethics 1.1.5 framework governs off-label and compounded prescribing decisions including documented risk-benefit assessment and FDA-approved alternatives considered.

Strongest evidence

The FDA Compounding Quality Act of 2013 provides the strongest regulatory framework for US pharmacy compounding operations.

The FDA Compounding Quality Act of 2013 (Drug Quality and Security Act) provides the strongest regulatory anchoring for US pharmacy compounding. The framework operates under section 503 of the Federal Food, Drug, and Cosmetic Act. The 503A pathway operates under state pharmacy board licensure with verification through the state pharmacy board portal. The 503B pathway operates under FDA registration with verification through the FDA Drug Establishment Registration database. Both pathways require USP Chapter 797 sterile compounding compliance for sterile preparations and USP Chapter 800 hazardous drug handling compliance where applicable. PCAB accreditation provides voluntary additional quality verification through the PCAB website. The framework was enacted in response to the 2012 New England Compounding Center meningitis outbreak which caused over 60 deaths from contaminated compounded methylprednisolone injections.

Limitations

Neither 503A nor 503B receives FDA pre-market approval for the compounded product. The framework supports patient-specific or office-administered compounded preparation rather than FDA-reviewed efficacy and safety.

Neither 503A nor 503B receives FDA pre-market approval for the compounded product. The compounded product is prepared in accordance with patient-specific prescription (503A) or office-administered authorization (503B) rather than reviewed for safety and efficacy by FDA. Evidence base for compounded peptide preparations varies substantially. Some compounded peptides like compounded thymosin alpha-1 operate at L3 human trials evidence tier in international Zadaxin approval contexts. Other compounded peptides like compounded BPC-157 operate at L1 to L2 evidence tier with primarily preclinical evidence. AMA Code of Medical Ethics 1.1.5 framework provides ethical anchoring for the prescribing decision but does not substitute for FDA pre-market review. Salt-form variants of FDA-approved molecules face FDA enforcement and do not qualify under shortage list compounding. Insurance coverage for compounded peptide preparations is typically limited or absent compared to FDA-approved peptide drugs. The compounding pharmacy system operates as a legitimate parallel framework to commercial drug manufacturing but with different oversight and evidence requirements.

Assessment

The compounding pharmacy system is a well-established regulatory framework supporting legitimate medical need. Quality verification across multiple layers protects patient safety.

PSI's reading: the US pharmacy compounding system provides legitimate regulatory infrastructure for compounded preparations including compounded peptide therapy. The FDA Compounding Quality Act of 2013 (Drug Quality and Security Act framework) establishes 503A and 503B pathways with appropriate oversight. PCAB accreditation, USP Chapter 797 and 800 standards, and third-party testing provide multi-layered quality verification. Healthcare providers selecting compounding pharmacy partners typically verify state license (503A) or FDA registration (503B), PCAB accreditation status, USP Chapter 797 and 800 compliance, and third-party purity and potency testing documentation. AMA Code of Medical Ethics 1.1.5 framework governs the prescribing decision. The framework supports legitimate medical need while addressing patient safety concerns raised by historical compounding outbreaks. Specialty coordination across endocrinology, weight medicine, rheumatology, sports medicine, immunology, and infectious disease supports indication-appropriate compounded peptide therapy decisions. The PSI physician directory provides verified physicians applying AMA Code 1.1.5 framework to compounded peptide prescribing decisions.

How to Approach Your Decision

Limitations and Caveats

Neither 503A nor 503B receives FDA pre-market approval for the compounded product. The framework supports prescription compounding rather than FDA-reviewed efficacy and safety.
Evidence base for compounded peptide preparations varies substantially across compounds and indications. Evidence tier may range from preclinical to international human trials.
AMA Code of Medical Ethics 1.1.5 framework provides ethical anchoring but does not substitute for FDA pre-market review. The framework requires documented risk-benefit assessment.
Salt-form variants of FDA-approved molecules face FDA enforcement. Semaglutide sodium and semaglutide acetate do not qualify under shortage list compounding.
FDA shortage list windows for semaglutide and tirzepatide ended in 2024. Compounded GLP-1 preparation after the windows operates under different regulatory considerations.
Insurance coverage for compounded peptide preparations is typically limited or absent. Patients should expect cash payment for compounded peptide therapy.
Quality verification varies by pharmacy. PCAB accreditation, USP compliance, and third-party testing are not uniformly applied across compounding pharmacies.
State pharmacy board oversight intensity varies by state. Some states have more rigorous compounding pharmacy inspection programs than others.

What's Marketed vs What's Studied

7 common claims, corrected.

“Compounded peptides are FDA-approved drugs.”

Neither 503A nor 503B compounded preparations receive FDA pre-market approval. The framework supports patient-specific prescription compounding (503A) or office-administered authorization (503B) rather than FDA-reviewed efficacy and safety. AMA Code of Medical Ethics 1.1.5 framework governs the prescribing decision.

“Compounded peptides are the same as research-grade peptides sold online.”

Compounded peptides require a physician prescription and route through 503A or 503B pathways under the FDA Compounding Quality Act of 2013. Research-grade peptides labeled not for human use operate outside the validated clinical practice framework entirely. The categories are legally and clinically distinct.

“503A and 503B pathways are equivalent regulatory frameworks.”

The pathways are distinct. 503A operates under state pharmacy board licensure with patient-specific prescription requirements. 503B operates under FDA registration permitting office-administered preparations without patient-specific prescriptions. Different oversight authorities and inspection frameworks apply.

“PCAB accreditation is required for compounding pharmacies.”

PCAB accreditation is voluntary additional quality verification beyond mandatory state pharmacy board licensure (503A) or FDA registration (503B). PCAB accreditation provides quality assurance signal but is not required for compounding pharmacy operation.

“Compounded semaglutide and tirzepatide remain legal in 2026 under shortage list framework.”

FDA removed semaglutide from the shortage list in October 2024. FDA removed tirzepatide from the shortage list in December 2024. The shortage list compounding framework windows ended for these compounds. Current compounding operates under different regulatory considerations.

“Salt-form variants of FDA-approved molecules are legitimate compounded preparations.”

Semaglutide sodium and semaglutide acetate are not the FDA-approved semaglutide base molecule. The FDA has issued warning letters and enforcement actions against compounding of salt-form variants. The variants do not qualify under shortage list compounding framework.

“All compounding pharmacies provide equivalent quality.”

Quality verification varies by pharmacy. PCAB accreditation, USP Chapter 797 and 800 compliance, third-party purity and potency testing, and state pharmacy board inspection records vary across pharmacies. Healthcare providers verify multiple quality dimensions when selecting compounding pharmacy partners.

Common Questions

What is the FDA Compounding Quality Act of 2013?

The FDA Compounding Quality Act of 2013 operates under the Drug Quality and Security Act framework. The act establishes two compounding categories: 503A traditional compounding pharmacies and 503B outsourcing facilities. The act was enacted in response to the 2012 New England Compounding Center meningitis outbreak which caused over 60 deaths from contaminated compounded methylprednisolone injections.

What is the difference between 503A and 503B?

503A covers traditional compounding pharmacies under state pharmacy board licensure with patient-specific prescription requirements. 503B covers FDA-registered outsourcing facilities authorized for office-administered preparations without patient-specific prescriptions. State license verification (503A) is through state pharmacy board portals. FDA registration verification (503B) is through the FDA Drug Establishment Registration database.

What is PCAB accreditation?

Pharmacy Compounding Accreditation Board (PCAB) accreditation is voluntary additional quality verification provided by an independent accreditation body. PCAB accreditation requires compliance with PCAB standards covering pharmacy operations, sterile compounding, non-sterile compounding, and quality management. Accreditation includes on-site inspection by PCAB inspectors. Verification is through the PCAB website.

What is USP General Chapter 797?

USP General Chapter 797 establishes sterile compounding standards for pharmaceutical compounding. The chapter covers aseptic technique requirements, environmental monitoring, beyond-use dating, personnel qualification, garbing and hand hygiene, and quality assurance documentation. The chapter applies to all sterile preparations including injectable peptide preparations.

What is USP General Chapter 800?

USP General Chapter 800 establishes hazardous drug handling standards. The chapter covers worker safety protocols, patient safety protocols, environmental controls, personal protective equipment requirements, spill management procedures, and waste handling protocols. The chapter applies to facilities preparing hazardous drugs as defined by NIOSH.

How do I verify a 503A compounding pharmacy?

Verify 503A compounding pharmacy through the state pharmacy board portal for the state where the pharmacy operates. The portal provides license status, license number, license expiration, and inspection history. Additional verification includes PCAB accreditation status through the PCAB website and USP Chapter 797 and 800 compliance documentation.

How do I verify a 503B outsourcing facility?

Verify 503B outsourcing facility through the FDA Drug Establishment Registration database. The database provides FDA registration status, facility address, and registration history. Additional verification includes PCAB accreditation status, USP Chapter 797 and 800 compliance documentation, and FDA inspection history through the FDA inspection database.

What is the FDA shortage list framework?

The FDA shortage list compounding framework permits temporary compounding of FDA-approved drugs during documented shortages. The framework operates under FDA enforcement discretion. The shortage list is published at the FDA Drug Shortage Database. Compounding under the framework operates only while the drug is on the shortage list.

Why did compounded semaglutide become legal in 2022?

FDA placed semaglutide on the shortage list in March 2022 due to manufacturing capacity constraints with Novo Nordisk for Wegovy and Ozempic. The shortage list inclusion permitted compounded semaglutide preparation through 503A and 503B pathways during the shortage period. The framework operated as a legitimate temporary compounding authorization.

Is compounded semaglutide still legal after October 2024?

FDA removed semaglutide from the shortage list in October 2024 ending the shortage list compounding framework window. Compounded semaglutide preparation after October 2024 operates under different regulatory considerations including FDA enforcement priorities and AMA Code 1.1.5 documentation requirements. Discuss the current regulatory framework with your prescribing physician.

What about salt-form variants like semaglutide sodium?

Salt-form variants of FDA-approved molecules face FDA enforcement and do not qualify under shortage list compounding. Semaglutide sodium and semaglutide acetate are not the FDA-approved semaglutide base molecule. The FDA has issued warning letters and enforcement actions against compounding of salt-form variants outside the shortage list framework.

What is AMA Code of Medical Ethics 1.1.5?

AMA Code of Medical Ethics Opinion 1.1.5 (Off-Label and Investigational Use of Pharmaceuticals) governs off-label and compounded prescribing decisions. The framework requires documented risk-benefit assessment for the specific patient context, FDA-approved alternatives considered, monitoring requirements including baseline labs and follow-up cadence, and patient understanding through informed consent acknowledgment.

What third-party testing applies to compounded peptide preparations?

Third-party testing typically includes USP General Chapter 71 sterility testing (verifying absence of viable microorganisms), USP General Chapter 85 bacterial endotoxin testing (verifying absence of bacterial endotoxin contamination), and HPLC potency analysis (verifying active ingredient concentration). Some compounding pharmacies provide certificate of analysis documentation per batch.

What insurance coverage applies to compounded peptide therapy?

Insurance coverage for compounded peptide preparations is typically limited or absent compared to FDA-approved peptide drugs. Patients should expect cash payment for compounded peptide therapy. FDA-approved peptide drugs (Wegovy, Ozempic, Zepbound, Mounjaro, Forteo, Tymlos, Evenity, Tesamorelin, Vyleesi) may have insurance coverage with prior authorization depending on indication.

What quality verification should I request from my compounding pharmacy?

Verification should include state pharmacy license (503A) or FDA registration (503B) status, PCAB accreditation status, USP Chapter 797 sterile compounding compliance documentation, USP Chapter 800 hazardous drug handling compliance where applicable, third-party purity and potency testing (USP 71 sterility, USP 85 endotoxin, HPLC potency), and FDA inspection history (503B).

Can I use research-grade peptides as a substitute for compounded peptides?

No. Research-grade peptides labeled not for human use operate outside the validated clinical practice framework entirely. The products are not regulated under the FDA Compounding Quality Act framework. The products are not a legal substitute for physician-prescribed compounded preparations. Self-sourcing operates outside AMA Code 1.1.5 framework requirements.

Sourcing Checklist

Confirm physician prescription before any compounded peptide therapy.
Both 503A patient-specific prescription and 503B office-administered authorization require a physician prescription from a state medical board licensed physician.
Verify 503A state pharmacy license through state pharmacy board portal.
License verification is through the state pharmacy board portal for the state where the pharmacy operates. Verify current license status, license number, and inspection history.
Verify 503B FDA registration through FDA Drug Establishment Registration database.
FDA registration verification is through the FDA Drug Establishment Registration database. Verify current registration status, facility address, and inspection history.
Check PCAB accreditation status through the PCAB website.
PCAB accreditation provides additional voluntary quality verification beyond mandatory licensure. The PCAB website lists accredited pharmacies and outsourcing facilities.
Confirm USP General Chapter 797 sterile compounding compliance documentation.
USP 797 addresses aseptic technique, environmental monitoring, beyond-use dating, and personnel qualification for sterile preparations including injectable peptide preparations.
Confirm USP General Chapter 800 hazardous drug handling compliance where applicable.
USP 800 addresses worker safety, patient safety, environmental controls, personal protective equipment, and waste handling for hazardous drug compounding.
Request third-party purity and potency testing documentation.
Testing typically includes USP 71 sterility, USP 85 bacterial endotoxin, and HPLC potency analysis. Certificate of analysis documentation per batch supports quality verification.
Confirm AMA Code of Medical Ethics 1.1.5 documentation from prescribing physician.
Documentation includes risk-benefit assessment, FDA-approved alternatives considered, monitoring requirements, and patient understanding through informed consent.
Verify current FDA shortage list status for compounded GLP-1 receptor agonist preparations.
Semaglutide removed from shortage list October 2024. Tirzepatide removed December 2024. Current compounding operates under different regulatory considerations.

Regulatory Context

The US pharmacy compounding regulatory framework evolves continuously. FDA shortage list status updates affect compounding framework windows for individual compounds. FDA enforcement priorities shift over time. USP General Chapter 797 and 800 standards update periodically with revised standards. PCAB standards update on multi-year cycles. State pharmacy board oversight programs vary across states and evolve with state legislation. AMA Code of Medical Ethics framework provides stable foundational ethical anchoring. PSI tracks regulatory framework changes per the Editorial Standards review cadence including FDA shortage list status, FDA enforcement actions, USP standard revisions, and PCAB accreditation updates.

Comparison

Framework Element	Regulatory Authority	Verification Method	Application
503A Traditional Compounding Pharmacy	State Pharmacy Board	State pharmacy board portal license verification	Patient-specific prescription compounded preparations
503B Outsourcing Facility	FDA	FDA Drug Establishment Registration database	Office-administered compounded preparations without patient-specific prescription
PCAB Accreditation	Pharmacy Compounding Accreditation Board (independent)	PCAB website verification	Voluntary additional quality verification
USP General Chapter 797	United States Pharmacopeia	USP compliance documentation	Sterile compounding standards
USP General Chapter 800	United States Pharmacopeia	USP compliance documentation	Hazardous drug handling standards
FDA Shortage List Framework	FDA enforcement discretion	FDA Drug Shortage Database	Temporary compounding during documented shortages
AMA Code of Medical Ethics 1.1.5	American Medical Association	Physician documentation	Off-label and compounded prescribing framework
Third-Party Testing	Independent testing laboratories	Certificate of analysis documentation	USP 71 sterility, USP 85 endotoxin, HPLC potency

Who This Applies To

· Patient considering compounded peptide therapy and reviewing pharmacy quality verification.
· Adult considering compounded GLP-1 receptor agonist preparation in 2025-2026 regulatory context.
· Patient verifying 503A state pharmacy license through state pharmacy board portal.
· Patient verifying 503B FDA registration through FDA Drug Establishment Registration database.
· Adult considering compounded thymosin alpha-1 for off-label immune support context.
· Adult considering compounded BPC-157 for off-label tissue repair context.
· Patient confirming PCAB accreditation status through PCAB website verification.
· Adult evaluating compounding pharmacy USP Chapter 797 and 800 compliance documentation.
· Patient considering third-party purity and potency testing documentation requirements.
· Physician selecting compounding pharmacy partners for office-administered preparations.

Verdict

The US pharmacy compounding system operates under the FDA Compounding Quality Act of 2013 establishing 503A traditional pharmacy and 503B outsourcing facility pathways. Neither receives FDA pre-market approval. Quality verification includes state license or FDA registration, PCAB accreditation, USP Chapter 797 and 800 compliance, and third-party testing. The FDA shortage list framework permitted temporary compounding of semaglutide and tirzepatide through 2024. AMA Code of Medical Ethics 1.1.5 framework governs the prescribing decision. The framework supports legitimate medical need with appropriate oversight.

In Plain Terms

The US has two main pathways for compounded medications. The 503A pathway covers traditional compounding pharmacies. The pharmacy needs a state license. Each prescription is for a specific patient. The 503B pathway covers larger facilities. They register with FDA. They can make compounded medicines for doctor offices without a patient-specific prescription. Neither pathway gets FDA approval for the final product. Quality checks include PCAB accreditation, USP standards, and third-party testing. Always verify the pharmacy quality with your doctor.

Compounding pharmacies make custom medicines. There are two types. Traditional pharmacies (503A) need a state license and a prescription for a specific patient. Larger facilities (503B) register with FDA and supply doctor offices. Neither type is FDA-approved for the specific compounded product. Quality verification includes special accreditation, standard practices, and testing. Always discuss compounded medications with your doctor before starting.

Compounding pharmacy selection requires physician verification of state license or FDA registration, PCAB accreditation, USP compliance, and third-party testing documentation. The methodology supports informed discussion but does not substitute for physician clinical judgment. PSI maintains a vetted directory of practitioners applying AMA Code 1.1.5 framework to compounded peptide prescribing decisions.

Find a verified physician

PSI's directory only lists physicians who have passed a five-gate verification process: state board active, no disciplinary actions, peptide-category competency, transparent pricing, and patient outcome documentation.

Browse the directory Learn about the verification process →

Related Conditions

Related Education

Featured Compounds

Common Contexts

· Patient considering compounded peptide therapy and reviewing pharmacy quality
· Adult considering compounded GLP-1 receptor agonist in 2025-2026 context
· Patient verifying 503A state pharmacy license
· Patient verifying 503B FDA registration
· Adult considering compounded thymosin alpha-1 for off-label immune support
· Adult considering compounded BPC-157 for off-label tissue repair
· Patient confirming PCAB accreditation status
· Adult evaluating USP Chapter 797 and 800 compliance
· Patient reviewing third-party testing documentation
· Physician selecting compounding pharmacy partners

Important Context

This page is educational and does not constitute medical advice. The information presented reflects the FDA Compounding Quality Act of 2013 (Drug Quality and Security Act framework), USP General Chapter 797 sterile compounding standards, USP General Chapter 800 hazardous drug handling standards, Pharmacy Compounding Accreditation Board (PCAB) standards, state pharmacy board licensure frameworks, FDA Drug Shortage Database, and AMA Code of Medical Ethics 1.1.5 and 2.1.1 frameworks for off-label and compounded prescribing context.

Your physician will select compounding pharmacy partners based on quality verification including state license or FDA registration, PCAB accreditation status, USP Chapter 797 and 800 compliance, and third-party testing documentation. The framework described here is general and does not substitute for individualized clinical judgment regarding compounded peptide therapy decisions. Specialty coordination supports complex contexts.

Self-sourcing of compounded peptide preparations outside physician prescribing pathways operates outside the validated clinical practice framework. Research-grade peptide products labeled not for human use are not regulated under the FDA Compounding Quality Act framework and are not a legal substitute for physician-prescribed compounded preparations.

Educational content only. The compounding pharmacy system framework supports informed discussion. Dosing should be determined by a qualified physician who can evaluate your individual situation. PSI does not provide personalized clinical recommendations or specific compounding pharmacy referrals. Always discuss compounded peptide therapy decisions with your prescribing physician.

Sources and Citations

[1] FDA Compounding Quality Act of 2013 (Drug Quality and Security Act): 503A pharmacy and 503B outsourcing facility framework · US Food and Drug Administration · 2013 · Source
[2] FDA Compounding and the FDA: Questions and Answers covering 503A and 503B framework distinctions · US Food and Drug Administration · 2024 · Source
[3] FDA Drug Shortage Database: published shortage list for compounding framework reference · US Food and Drug Administration · 2024 · Source
[4] FDA Drug Establishment Registration database: 503B outsourcing facility registration verification · US Food and Drug Administration · 2024 · Source
[5] USP General Chapter 797 Pharmaceutical Compounding - Sterile Preparations · United States Pharmacopeia · 2023 · Source
[6] USP General Chapter 800 Hazardous Drugs - Handling in Healthcare Settings · United States Pharmacopeia · 2023 · Source
[7] Pharmacy Compounding Accreditation Board (PCAB) Standards for compounding pharmacy and outsourcing facility quality verification · Pharmacy Compounding Accreditation Board · 2024 · Source
[8] AMA Code of Medical Ethics Opinion 1.1.5: Off-label and Investigational Use of Pharmaceuticals · American Medical Association · 2024 · Source
[9] AMA Code of Medical Ethics Opinion 2.1.1: Informed Consent · American Medical Association · 2024 · Source
[10] American Diabetes Association. Standards of Care in Diabetes 2024 · Diabetes Care · 2024 · DOI
[11] FDA Prescribing Information: Wegovy (semaglutide) injection · 2024 · FDA NDA 215256 · Source
[12] Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT trial) · New England Journal of Medicine · 2023 · DOI

Medical Disclaimer

This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.